+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Endometrial Cancer - Pipeline Review, H2 2020

  • PDF Icon

    Drug Pipelines

  • 1759 Pages
  • November 2020
  • Region: Global
  • Global Markets Direct
  • ID: 5229494
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Endometrial Cancer - Pipeline Review, H2 2020, provides an overview of the Endometrial Cancer (Oncology) pipeline landscape.

Endometrial cancer is cancer that starts in the endometrium, the lining of the uterus (womb). Endometrial cancer is the most common type of uterine cancer. Although the exact cause of endometrial cancer is unknown, increased levels of estrogen appear to play a role. Estrogen helps stimulate the buildup of the lining of the uterus. Symptoms of endometrial cancer include abnormal bleeding from the vagina, including bleeding between periods or spotting/bleeding after menopause, extremely long, heavy or frequent episodes of vaginal bleeding after age 40, lower abdominal pain or pelvic cramping and thin white or clear vaginal discharge after menopause.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Endometrial Cancer - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Endometrial Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Endometrial Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Endometrial Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 10, 84, 66, 3, 20, 5 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 4, 2 and 2 molecules, respectively.

Endometrial Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Endometrial Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Endometrial Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Endometrial Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Endometrial Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Endometrial Cancer (Oncology)

Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Endometrial Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Endometrial Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Introduction

Endometrial Cancer - Overview

Endometrial Cancer - Therapeutics Development

Endometrial Cancer - Therapeutics Assessment

Endometrial Cancer - Companies Involved in Therapeutics Development

Endometrial Cancer - Drug Profiles

Endometrial Cancer - Dormant Projects

Endometrial Cancer - Discontinued Products

Endometrial Cancer - Product Development Milestones

Appendix

List of Tables
  • Number of Products under Development for Endometrial Cancer, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Endometrial Cancer - Pipeline by Aadi Bioscience Inc, H2 2020
  • Endometrial Cancer - Pipeline by Ability Pharmaceuticals SL, H2 2020
  • Endometrial Cancer - Pipeline by Abpro Corp, H2 2020
  • Endometrial Cancer - Pipeline by Acepodia Biotech Inc, H2 2020
  • Endometrial Cancer - Pipeline by Acrotech Biopharma LLC, H2 2020
  • Endometrial Cancer - Pipeline by Adlai Nortye Biopharma Co Ltd, H2 2020
  • Endometrial Cancer - Pipeline by Advenchen Laboratories LLC, H2 2020
  • Endometrial Cancer - Pipeline by Agenus Inc, H2 2020
  • Endometrial Cancer - Pipeline by Allarity Therapeutics A/S, H2 2020
  • Endometrial Cancer - Pipeline by Almac Discovery Ltd, H2 2020
  • Endometrial Cancer - Pipeline by Alphamab Oncology, H2 2020
  • Endometrial Cancer - Pipeline by Amgen Inc, H2 2020
  • Endometrial Cancer - Pipeline by Amphivena Therapeutics Inc, H2 2020
  • Endometrial Cancer - Pipeline by Apexian Pharmaceuticals Inc, H2 2020
  • Endometrial Cancer - Pipeline by Apexigen Inc, H2 2020
  • Endometrial Cancer - Pipeline by Apollomics Inc, H2 2020
  • Endometrial Cancer - Pipeline by Arch Oncology Inc, H2 2020
  • Endometrial Cancer - Pipeline by Arcus Biosciences Inc, H2 2020
  • Endometrial Cancer - Pipeline by Arrien Pharmaceuticals LLC, H2 2020
  • Endometrial Cancer - Pipeline by Ascenta Therapeutics Inc, H2 2020
  • Endometrial Cancer - Pipeline by AstraZeneca Plc, H2 2020
  • Endometrial Cancer - Pipeline by Bantam Pharmaceutical LLC, H2 2020
  • Endometrial Cancer - Pipeline by Bavarian Nordic A/S, H2 2020
  • Endometrial Cancer - Pipeline by Bayer AG, H2 2020
  • Endometrial Cancer - Pipeline by BeiGene Ltd, H2 2020
  • Endometrial Cancer - Pipeline by Beijing Neoantigen Biotechnology Co Ltd, H2 2020
  • Endometrial Cancer - Pipeline by Bicycle Therapeutics Plc, H2 2020
  • Endometrial Cancer - Pipeline by Bio-Path Holdings Inc, H2 2020
  • Endometrial Cancer - Pipeline by BioAtla LLC, H2 2020
  • Endometrial Cancer - Pipeline by BioMed Valley Discoveries Inc, H2 2020
  • Endometrial Cancer - Pipeline by BioNTech SE, H2 2020
  • Endometrial Cancer - Pipeline by Black Diamond Therapeutics Inc, H2 2020
  • Endometrial Cancer - Pipeline by Boehringer Ingelheim International GmbH, H2 2020
  • Endometrial Cancer - Pipeline by Bristol-Myers Squibb Co, H2 2020
  • Endometrial Cancer - Pipeline by Byondis BV, H2 2020
  • Endometrial Cancer - Pipeline by Carrick Therapeutics Ltd, H2 2020
  • Endometrial Cancer - Pipeline by Celon Pharma SA, H2 2020
  • Endometrial Cancer - Pipeline by Celsion Corp, H2 2020
  • Endometrial Cancer - Pipeline by Checkpoint Therapeutics Inc, H2 2020
  • Endometrial Cancer - Pipeline by Clovis Oncology Inc, H2 2020
  • Endometrial Cancer - Pipeline by Compugen Ltd, H2 2020
  • Endometrial Cancer - Pipeline by Context Therapeutics LLC, H2 2020
  • Endometrial Cancer - Pipeline by Corvus Pharmaceuticals Inc, H2 2020
  • Endometrial Cancer - Pipeline by Cotinga Pharmaceuticals Inc, H2 2020
  • Endometrial Cancer - Pipeline by CStone Pharmaceuticals Co Ltd, H2 2020
  • Endometrial Cancer - Pipeline by Cue Biopharma Inc, H2 2020
  • Endometrial Cancer - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2020
  • Endometrial Cancer - Pipeline by Daiichi Sankyo Co Ltd, H2 2020
  • Endometrial Cancer - Pipeline by Deciphera Pharmaceuticals Inc, H2 2020
  • Endometrial Cancer - Pipeline by Dragonfly Therapeutics Inc, H2 2020
  • Endometrial Cancer - Pipeline by Eisai Co Ltd, H2 2020
  • Endometrial Cancer - Pipeline by Eli Lilly and Co, H2 2020
  • Endometrial Cancer - Pipeline by Elicio Therapeutics, H2 2020
  • Endometrial Cancer - Pipeline by ENB Therapeutics LLC, H2 2020
  • Endometrial Cancer - Pipeline by Esperance Pharmaceuticals Inc, H2 2020
  • Endometrial Cancer - Pipeline by Esperas Pharma Inc, H2 2020
  • Endometrial Cancer - Pipeline by EstryX Pharma Ltd, H2 2020
  • Endometrial Cancer - Dormant Projects, H2 2020
  • Endometrial Cancer - Discontinued Products, H2 2020

List of Figures
  • Number of Products under Development for Endometrial Cancer, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Top 10 Routes of Administration, H2 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2020
  • Number of Products by Top 10 Molecule Types, H2 2020
  • Number of Products by Stage and Top 10 Molecule Types, H2 2020

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Aadi Bioscience Inc
  • Ability Pharmaceuticals SL
  • Abpro Corp
  • Acepodia Biotech Inc
  • Acrotech Biopharma LLC
  • Adlai Nortye Biopharma Co Ltd
  • Advenchen Laboratories LLC
  • Agenus Inc
  • Allarity Therapeutics A/S
  • Almac Discovery Ltd
  • Alphamab Oncology
  • Amgen Inc
  • Amphivena Therapeutics Inc
  • Apexian Pharmaceuticals Inc
  • Apexigen Inc
  • Apollomics Inc
  • Arch Oncology Inc
  • Arcus Biosciences Inc
  • Arrien Pharmaceuticals LLC
  • Ascenta Therapeutics Inc
  • AstraZeneca Plc
  • Bantam Pharmaceutical LLC
  • Bavarian Nordic A/S
  • Bayer AG
  • BeiGene Ltd
  • Beijing Neoantigen Biotechnology Co Ltd
  • Bicycle Therapeutics Plc
  • Bio-Path Holdings Inc
  • BioAtla LLC
  • BioMed Valley Discoveries Inc
  • BioNTech SE
  • Black Diamond Therapeutics Inc
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co
  • Byondis BV